
    
      PRIMARY OBJECTIVES:

      I. Overall response defined as achievement of complete response (CR) or partial response
      (PR).

      SECONDARY OBJECTIVES:

      I. Safety of the combination. II. Response according to prognostic markers at diagnosis. III.
      Time to next treatment. IV. Overall survival.

      OUTLINE:

      Patients receive obinutuzumab intravenously (IV) over 3-4 hours on days 1, 2, 8, and 15 of
      course 1 and day 1 of courses 2-6 and lenalidomide orally (PO) once daily (QD) on days 9-28
      of course 1 and days 1-28 of all subsequent courses. Treatment repeats every 28 days for up
      to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may
      continue to receive lenalidomide PO QD in the absence of disease progression or unacceptable
      toxicity.
    
  